scholarly journals Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients

2015 ◽  
Vol 100 (7) ◽  
pp. 2666-2672 ◽  
Author(s):  
Mauro Rigato ◽  
Cristina Bittante ◽  
Mattia Albiero ◽  
Angelo Avogaro ◽  
Gian Paolo Fadini
Keyword(s):  
False Discovery Rate ◽  
Cell Count ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Diabetic Patients ◽  
Endothelial Progenitor ◽  
False Discovery ◽  
Type 2 Diabetic

Context: Diabetes reduces the levels of circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs), which promote vascular repair and are inversely correlated with cardiovascular risk. Objective: The objective of the study was to test whether CPC/EPC levels predict onset/progression of microangiopathy in a cohort of type 2 diabetic (T2D) patients. Design: This was a pseudoprospective study with a 3.9-year follow-up. Setting: The study was conducted at a tertial referral diabetes outpatient clinic. Patients: A total of 187 T2D patients having a baseline determination of CPCs/EPCs participated in the study. Intervention: Baseline data on demographics, anthropometrics, concomitant risk factors, diabetic complications, and medications were collected. Main Outcome Measure: Onset or progression of microangiopathy was assessed at follow-up compared with baseline. Results: New onset or progression of microalbuminuria, chronic kidney disease, retinopathy, and neuropathy occurred in 70 patients (9.5%/y). After controlling the false discovery rate, baseline CD34+ CPCs and EPCs were significantly lower in patients with onset/progression of microalbuminuria and any microangiopathy. Patients with baseline CD34+ CPC or CD133+/kinase insert domain-containing receptor+/EPC levels below the median were more likely to experience worsening microangiopathy than those with high cell levels. Independently from confounders, including age, sex, glycated hemoglobin, and diabetes duration, CD34+ cells predicted onset/progression of microalbuminuria, retinopathy, and any microangiopathy in false discovery rate-adjusted analyses. A low CD34+ cell count limited the beneficial effects of renin-angiotensin system blockers on microalbuminuria progression. Conclusions: Levels of circulating (endothelial) progenitor cells predict microvascular outcomes in T2D. Together with previous studies showing an association with cardiovascular events, these data indicate that CPCs/EPCs represent biomarkers of the global complication burden in diabetes.

Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients

2015 ◽  
Vol 67-69 ◽  
pp. 21-29 ◽  
Author(s):  
Gian Paolo Fadini ◽  
Mauro Rigato ◽  
Federico Boscari ◽  
Roberta Cappellari ◽  
Lisa Menegazzo ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Diabetic Patients ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Endothelial Progenitor ◽  
Type 2 Diabetic

Impaired development and dysfunction of endothelial progenitor cells in type 2 diabetic mice

2017 ◽  
Vol 43 (2) ◽  
pp. 154-162 ◽  
Author(s):  
S. Tsukada ◽  
H. Masuda ◽  
S.Y. Jung ◽  
J. Yun ◽  
S. Kang ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Diabetic Mice ◽  
Endothelial Progenitor ◽  
Type 2 Diabetic

Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

2017 ◽  
Vol 125 (06) ◽  
pp. 400-407 ◽  
Author(s):  
Fang Li ◽  
Jiachao Chen ◽  
Fei Leng ◽  
Zhiqiang Lu ◽  
Yan Ling
Keyword(s):  
Endothelial Function ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Metformin Group ◽  
Significant Difference ◽  
Type 2 Diabetic

Abstract Endothelial dysfunction is associated with the risk of cardiovascular complications in diabetic patients. Endothelial progenitor cells (EPCs) and flow-mediated dilation (FMD) are common markers of endothelial function. In this study, we aim to investigate whether the DPP-4 inhibitor saxagliptin modulate EPCs number and FMD in newly diagnosed, treatment-naive type 2 diabetic patients. This was a controlled, randomized, open-label clinical trial. Saxagliptin group and metformin group consumed either saxagliptin 5 mg per day or metformin 1 500 mg per day respectively for 12 weeks. Changes of FMD and EPCs number after 12-week intervention were the primary endpoints. 31 patients were initially enrolled and randomized to saxagliptin group (n=16) and metformin group (n=15). 27 patients completed the trial (saxagliptin group n=14 and metformin group n=13), and 4 patients dropped out during the study. FMD and EPCs number increased significantly in both saxagliptin group and metformin group, and there was no significant difference between groups. 2-h postprandial plasma glucose, HbA1c and diastolic blood pressure improved significantly in both groups, and there was no significant difference between groups. Saxagliptin and metformin had comparable beneficial effects on endothelial function.

Prompt Increases in Serum RBP4 and Endothelial Progenitor Cells Following Exercise Load in Type 2 Diabetic Subjects

2011 ◽  
pp. P2-541-P2-541
Author(s):  
Atsushi Aoki ◽  
Miho Murata ◽  
Tomoko Asano ◽  
Masami Sasaki ◽  
Aki Ikoma ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
Exercise Load ◽  
Type 2 Diabetic

Autologous Skin Fibroblast and Keratinocyte Grafts in the Treatment of Chronic Foot Ulcers in Aging Type 2 Diabetic Patients

2011 ◽  
Vol 101 (1) ◽  
pp. 55-58 ◽  
Author(s):  
Matteo Monami ◽  
Maria Vivarelli ◽  
Carla Maria Desideri ◽  
Giulio Ippolito ◽  
Niccolò Marchionni ◽  
...  
Keyword(s):  
Healing Time ◽  
Lower Limbs ◽  
Foot Ulcers ◽  
Diabetic Patients ◽  
Consecutive Series ◽  
Type 2 Diabetic Patients ◽  
Skin Cell ◽  
Type 2 Diabetic

Background: We assessed the tolerability and efficacy of autologous skin cell grafts in older type 2 diabetic patients with chronic foot ulcers. Methods: Treatment with Hyalograft 3D and Laserskin Autograft was proposed to a consecutive series of type 2 diabetic patients older than 65 years affected by long-standing (>6 months) foot ulcers with an area greater than 15 cm2. Ulcer healing rates and measurements of ulcer area were determined monthly for 12 months. Results: Seven patients with 12 ulcers, nine of which received the described treatment, were enrolled. During 12-month follow-up, all of the ulcers healed except one. In the remaining eight ulcers, the median healing time was 21 weeks (interquartile range, 4–29 weeks). Conclusions: Autologous skin cell grafts are feasible, well tolerated, and apparently effective in the treatment of diabetic ulcers of the lower limbs in advanced age. Age did not seem to moderate healing times. (J Am Podiatr Med Assoc 101(1): 55–58, 2011)

Sign in / Sign up

Export Citation Format

Share Document